The Form 4 filing, an SEC report of insider stock activity, was filed on October 29, 2026. The reported sales span October 27–28, 2026.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-27 |
| Date of Latest Transaction | 2026-10-28 |
| Buy/Sell | sell |
| Transaction Count | 2 |
| Shares Transacted | 2,172 |
| Price | $416.88 |
| Total Transaction Value | $905,467.54 |
| Insider | |
| Ticker Symbol | NTRA |
| Company | Natera, Inc. |
| Insider Name | Moshkevich Solomon |
| Insider Title | PRESIDENT, CLINICALDIAGNOSTICS |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 104,742 |
| Position Size Change | 2.03% |
| Filing | |
| Filing Date | 2026-10-29 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were two share sales, reported under SEC transaction code S. The available transaction details identify sales with a link to tax coverage or payment of a stock-option exercise price.
What was the average price of the transaction?
The average sale price was $416.88 per share across the two transactions. Separate prices for each sale were not provided.
How did this transaction affect the insider's holdings?
Solomon Moshkevich sold 2,172 shares and reported owning 104,742 shares afterward. The shares sold made up 2.03% of his reported shares owned before the sales.
What's the total transaction value?
The two sales totaled $905,467.5448, or $905,467.54 rounded to cents. That total covers both transactions.
Are there any special circumstances around this transaction?
Yes. The transaction details include a Rule 10b5-1 plan reference. These plans set trading instructions in advance. The available information does not establish which of the two sales the plan reference covers or when the plan began.
The details also link the sales to covering taxes or paying an exercise price. An exercise price is the set price paid to buy shares through a stock option. The S code identifies the transactions as sales.
The filing footnotes were not provided, so the exact payment purpose remains unknown. The available details do not confirm whether sale proceeds covered taxes, the cost of using stock options, or both. They do not establish that taxes were the only purpose.
For research purposes only; not investment advice.